Synosia Therapeutics
Therapeutics developer for central nervous system disorders.
| Date | Investors | Amount | Round |
|---|---|---|---|
| N/A | €0.0 | round | |
| investor investor investor | €0.0 | round | |
| investor investor investor investor investor investor | €0.0 | round | |
| investor investor investor investor investor investor investor | €0.0 | round | |
$122m | Acquisition | ||
| Total Funding | 000k | ||
Synosia Therapeutics was a Swiss-based drug development company founded in 2005, specializing in treatments for central nervous system (CNS) disorders. The company was co-founded by Dr. Ian Massey, a veteran drug development executive with extensive experience at Roche and Syntex, who also served as President and CEO. Massey's background in neuroscience drug development was central to Synosia's strategy, which focused on acquiring or in-licensing clinical-stage assets to accelerate their path to market.
The company's business model was centered on forming strategic partnerships with major pharmaceutical firms to develop compounds that had been deprioritized. In 2007, Synosia entered into a significant agreement with Roche to develop a portfolio of five drug candidates for conditions like schizophrenia, cognitive disorders, and Parkinson's disease. This was followed by agreements with Novartis and Syngenta, expanding its pipeline to six clinical-stage compounds. A key candidate was SYN-115, an adenosine A2a antagonist for Parkinson's disease, acquired from Roche.
Synosia successfully raised significant capital to fund its clinical programs, including a $32.5 million initial funding, a $29 million Series B in 2009, and a $30 million Series C round in 2010. The Series C was led by UCB Pharma, which also entered into a strategic alliance potentially worth up to $725 million for two of Synosia's Parkinson's drugs, SYN-115 and SYN-118. In February 2011, Synosia Therapeutics was acquired by the Finnish drug development company Biotie Therapies in a deal valued at approximately €93.6 million (around $122M). Following the acquisition, Dr. Massey took on the role of COO and President of US Operations at Biotie.
Keywords: central nervous system, CNS disorders, drug development, neurology, psychiatry, Parkinson's disease, clinical trials, therapeutics, Roche partnership, Biotie Therapies acquisition, Ian Massey, biopharmaceutical, clinical-stage assets, drug licensing, venture capital, UCB Pharma, SYN-115, adenosine A2a antagonist, neuroscience, drug discovery